Drug intelligence / Profile preview

etomidate + morphine

Development stage: Unknown
Lead developer: Janssen Pharmaceutica
Modality: Small Molecules
Administration: Intravenous

Overview

Etomidate and morphine combination is used for induction of anesthesia. Etomidate is a short-acting intravenous anesthetic that acts at the level of the reticular-activating system to produce anesthesia. It appears to depress CNS function via GABA. Morphine is a narcotic analgesic that acts on the central nervous system to relieve pain. When combined, studies have shown that this combination can lead to unsatisfactory results with common occurrences of hypertension or hypotension depending on the dose given.

Targets

GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on etomidate + morphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on etomidate + morphine.

Explore the full profile